Chembio Files for CLIA Waiver with FDA for Point-of-Care DPP(R) HIV 1/2 Assay

Chembio Files for CLIA Waiver with FDA for Point-of-Care DPP(R) HIV 1/2 Assay

MEDFORD, N.Y., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI), a leader in point-of-care ("POC") diagnostic tests for
infectious diseases, has completed its Clinical Laboratory Improvement
Amendment ("CLIA") waiver studies for its DPP® HIV 1/2 Assay (the "Assay").
The Company believes the study results meet CLIA waiver requirements and it
has filed the CLIA waiver application with the U.S. Food and Drug
Administration ("FDA").

In support of the application to the FDA Chembio sponsored studies at multiple
sites evaluating the accuracy and simplicity of the Assay. The Assay is a
rapid, POC assay for the detection of HIV 1/2 antibodies in either oral fluid
or blood samples. Approximately 1,100 individuals infected with HIV, or at
risk for infection with HIV, participated in the studies, which included
testing on oral fluid, finger-stick whole blood and venous whole blood samples
from each patient.

A CLIA waiver will allow Chembio to make the test available to customers
addressing the widest possible range of at-risk individuals in the U.S., such
as in outreach clinics, community-based organizations and physician offices
(See "About CLIA Waiver" below). Although there is no statutory time in which
the FDA must review a CLIA waiver application, Chembio anticipates that it
will receive a CLIA waiver of the Assay from the FDA in order to launch this
product in the U.S. during the second quarter of 2014, as planned.

"Despite a significant increase in awareness, there are still nearly 50,000
new HIV infections diagnosed every year in the U.S.," stated Lawrence Siebert,
Chembio's chief executive officer."The fact that nearly 1 in 5 people with
HIV don't know they are infected contributes to the spread of this
disease.Our DPP® HIV 1/2 Assay has several attractive and unique features,
including oral fluid collection, a user-friendly collection swab, and enhanced
sample retention and processing safety via the SampleTainer® processing
device.Therefore a CLIA waiver of this product will provide an important new
option in the United States rapid HIV testing market." 

The announcement of Chembio's CLIA waiver application immediately follows
yesterday's observance of World AIDS Day.World AIDS Day is held on December
1^st each year and is dedicated to raising HIV awareness globally.While there
have been many advances in the fight against HIV/AIDS, it has tragically
claimed more than 25 million lives since 1981, and there are more than 35
million people currently living with the infection worldwide.

"All of us at Chembio commemorate World AIDS Day by renewing our commitment to
develop and deliver high-quality, cost-effective HIV rapid tests worldwide,
and to support prevention programs," added Siebert."In light of the 2013
recommendations by the U.S. Preventive Services Task Force that HIV testing be
an A-rated preventive service, it is anticipated that more of the estimated
250,000 HIV-positive Americans who are currently unaware of their disease,
will be tested and referred to care to manage their disease with increasingly
effective therapies.We believe that there will be an increased demand for
testing in the U.S. as a result, and that Chembio is well positioned for
serving this demand.As we continue to grow our presence in the U.S. market,
Chembio remains the only U.S.-based manufacturer of cost-effective
FDA-approved rapid HIV tests to private, governmental and non-governmental
organizations and programs globally, many of which are funded by the United
States through the President's Emergency Plan for AIDS Relief ("PEPFAR")."

About Chembio's DPP® HIV 1/2 Assay

The rapid POC DPP^® HIV 1/2 Assay (the "Assay") was first approved by FDA's
Center for Biologics Evaluation & Research ("CBER") in December 2012 as a
Pre-Marketing Approval ("PMA") of a "moderately complex" biological
product.With such approval a CLIA waiver application for this product could
be filed with FDA's Center for Devices & Radiological Health ("CDRH"), which
Chembio has now done. The Assay is based on Chembio's innovative and patented
Dual Path Platform technology, or DPP®. The Assay detects antibodies to HIV-1
and HIV-2 in finger-stick whole blood, venous whole blood, serum, or plasma
samples within approximately 15 minutes, and also has a number of
differentiating performance features and claims, including the ability to use
an oral fluid sample with the Assay. The Assay includes a proprietary
SampleTainer® collection system, is easy to use, has a uniform procedure
across all sample matrices, and provides the user with a clear read-out of
results.

For more information about the Company's POC DPP^® HIV 1/2 Assay, please visit
http://chembio.com/products/human-diagnostics/dpp-hiv-12-assay/.

About CLIA Waiver

CLIA waiver is granted by the CDRH for tests that are categorized as simple or
low ("waived") complexity and that are demonstrated to have an insignificant
risk of an erroneous result. Tests of "moderate" and "high" complexity may
only be run by sophisticated laboratories that meet stringent requirements
under CLIA. Most CLIA requirements are waived, however, if a laboratory only
employs tests of low complexity.

More than 6.8 billion laboratory tests are performed each year in the United
States.Waived labs account for roughly 60% of the 230,000 clinical
laboratories in the United States. The vast majority of waived labs are in
physicians' offices and other facilities in close proximity to patients and
health-care providers. The closeness of these labs to patients allows for
point-of-care testing ("POCT"), where health-care providers get results in
real time as opposed to sending patient specimens to off-site laboratories and
waiting days or weeks for results. POCT can provide faster diagnosis and
treatment decisions, made while a patient is actually in a doctor's office.
POCT for also may prevent situations where patients fail to return to their
provider in order to get the information or treatment they need, and to reduce
the risk of transmission to additional people in the event of a positive
result.For sexually transmitted diseases such as HIV, this can contribute
both to improved patient and public health outcomes.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc.Chembio markets its HIV STAT-PAK® line
of rapid HIV tests internationally to government and donor-funded programs
directly and through distributors. Chembio has developed a patented
point-of-care test platform technology, the Dual Path Platform (DPP®)
technology, which has significant advantages over lateral-flow technologies.
This technology is providing Chembio with a significant pipeline of business
opportunities for the development and manufacture of new products based on
DPP®. Headquartered in Medford, NY, with approximately 200 employees, Chembio
is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S.
Department of Agriculture (USDA), and is certified for the global market under
the International Standards Organization (ISO) directive 13.485. For more
information, please visit: www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended. Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management. Such
statements, which are estimates only, reflect management's current views, are
based on certain assumptions, and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to Chembio's
ability to obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products. Chembio
undertakes no obligation to publicly update these forward-looking statements
to reflect events or circumstances that occur after the date hereof or to
reflect any change in Chembio's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events. Factors
that may impact Chembio's success are more fully disclosed in Chembio's most
recent public filings with the U.S. Securities and Exchange Commission.

CONTACT: Chembio Diagnostics
         Susan Norcott
         (631) 924-1135, ext. 125
         snorcott@chembio.com
        
         Vida Strategic Partners (investor relations)
         Stephanie C. Diaz
         415-675-7401
         sdiaz@vidasp.com